Skip to content
DataLookout
Menu

NCT05077904

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later across 3 updates.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 93 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 1 of 183 sites
  2. Minor Primary and study completion pushed from Oct 31, 2026 to Mar 29, 2027
  3. Minor Primary and study completion pushed from Sep 30, 2026 to Oct 31, 2026
  4. Minor Site details revised at 1 of 183 sitesv90
  5. Minor Primary and study completion pushed from Aug 31, 2026 to Sep 30, 2026v89
  6. Minor Site details revised at 2 of 183 sitesv88
  7. Minor Primary and study completion pushed from Jul 31, 2026 to Aug 31, 2026
    • Site details revised at 5 of 183 sites
    v87
  8. Minor Primary and study completion pushed from Jun 30, 2026 to Jul 31, 2026v86
  9. Minor Site details revised at 5 of 183 sitesv85
  10. Minor Primary and study completion pushed from Apr 2026 to Jun 30, 2026
    • Site details revised at 2 of 183 sites
    v84
  11. Minor Study sites: 182 to 183v83
  12. Minor Primary and study completion dates: Apr 6, 2026 to Apr 2026v82
  13. Minor Primary and study completion dates: Apr 2026 to Apr 6, 2026
    • Site details revised at 3 of 182 sites
    v81
  14. Minor Primary and study completion dates: Apr 6, 2026 to Apr 2026v80
  15. Minor Study sites: 181 to 182v79
  16. Minor Study sites: 180 to 181v78
  17. Minor Site details revised at 1 of 180 sitesv77
  18. Minor Site details revised at 1 of 180 sitesv76
  19. Minor Site details revised at 1 of 180 sitesv75
  20. Minor Study sites: 177 to 180v74
  21. Minor Study sites revised (177)v73
  22. Minor Site details revised at 2 of 177 sitesv72
  23. Minor Study sites: 175 to 177v71
  24. Minor Study sites: 174 to 175v70
  25. Minor Site details revised at 1 of 174 sitesv69
  26. Minor Study sites: 173 to 174v68
  27. Minor Study sites: 169 to 173v67
  28. Minor Study sites: 166 to 169v66
  29. Minor Study sites: 165 to 166v65
  30. Minor Study sites: 164 to 165v64
  31. Minor Study sites: 163 to 164v63
  32. Minor Study sites: 162 to 163v62
  33. Minor Site details revised at 1 of 162 sitesv61
  34. Minor Study sites: 161 to 162v60
  35. Minor Study sites: 160 to 161v59
  36. Minor Study sites: 157 to 160v58
  37. Minor Enrollment target: 250 to 350v57
  38. Minor Site details revised at 1 of 157 sitesv56
  39. Minor Study sites: 156 to 157v55
  40. Minor Study sites: 154 to 156v54
  41. Notable Primary and study completion dates: Apr 17, 2024 to Apr 6, 2026
    • Study sites: 151 to 154
    v53
  42. Minor Site details revised at 2 of 151 sitesv51
  43. Minor Study sites: 150 to 151v50
  44. Minor Study sites: 149 to 150v49
  45. Minor Study sites: 147 to 149v48
  46. Minor Study sites: 146 to 147v47
  47. Minor Study sites: 144 to 146v46
  48. Minor Site details revised at 2 of 144 sitesv45
  49. Minor Study sites: 143 to 144v44
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
Timeframe: From start of IMP treatment through 6 hours
Treatment success for the treated seizure with no recurrence up to 2 hours
Timeframe: From start of IMP treatment through 2 hours

Secondary (6)

Treatment success for treated seizure with no recurrence after 4 hours
Treatment success for treated seizure with no recurrence after 6 hours
Time from IMP administration to cessation of the treated seizure
Frequency of respiratory treatment emergent adverse events (TEAEs)
Number of subsequent seizure(s) up to 2 hours after IMP administration
Show 1 moreShow less
Time to first subsequent seizure up to 2 hours after IMP administration

Arms and interventions

Staccato alprazolam ArmExperimental

Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.

Placebo ArmPlacebo comparator

Participants randomized to this arm will receive a single dose of placebo by inhalation.

Drugs: Staccato alprazolam

Other: Placebo

Sites

183 sites in 13 countries

United States 66, China 33, Japan 21, Poland 9, France 8, Germany 8, Spain 8, Italy 6, United Kingdom 6, Bulgaria 5, Czechia 5, Australia 4, Hungary 4